These promising probes could not only be useful for the diagnosis of c‐Met aberrant cancer but also could enable real‐time monitoring for the selection of patients for c‐Met targeting drugs by the identification of responding and nonresponding patients for c‐Met targeted therapeutics. The gene discussed is MET; the disease is cancer.